MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare form of solid tumour that affects around 2,000 people in the US each year. The green ...
MSD's efforts to combine cancer immunotherapy Keytruda with its AstraZeneca-partnered PARP drug Lynparza have so far failed – but at last it can point to a partial win in a phase 3 trial. The new data ...
Abstract: This article presents a novel dual linearly polarized shared-aperture 2-bit programmable metasurface (PMS) with high cross-polarization discrimination (XPD). Two orthogonally placed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback